Actelion Ltd (ATLN.VX)

ATLN.VX on Virt-X Level 1

116.40CHF
6:51am EST
Price Change (% chg)

CHF3.70 (+3.28%)
Prev Close
CHF112.70
Open
CHF114.50
Day's High
CHF116.50
Day's Low
CHF114.30
Volume
199,985
Avg. Vol
515,036
52-wk High
CHF118.00
52-wk Low
CHF71.90

ATLN.VX

Chart for ATLN.VX

About

Actelion Ltd is a Swiss biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled formulation of... (more)

Overall

Beta: 0.77
Market Cap (Mil.): CHF12,862.27
Shares Outstanding (Mil.): 114.13
Dividend: 1.20
Yield (%): 1.06

Financials

  ATLN.VX Industry Sector
P/E (TTM): 18.34 176.92 37.62
EPS (TTM): 6.14 -- --
ROI: 32.62 -0.38 17.39
ROE: 40.51 -1.43 18.30
Search Stocks

BRIEF-Actelion submits selexipag for EMA marketing authorisation in patients with pulmonary arterial hypertension

* Announced on Monday the submission of centralized Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for selexipag (Uptravi(R)) in treatment of pulmonary arterial hypertension (PAH)

02 Dec 2014

Actelion lifts 2014 profit view on strong Opsumit launch

ZURICH - Actelion raised its 2014 earnings guidance on Tuesday for the third time this year, buoyed by a strong start to its new heart and lung drug and better-than-expected profit in the third quarter.

21 Oct 2014

UPDATE 2-Actelion lifts 2014 profit view on strong Opsumit launch

* Shares up 6.8 pct (Adds details on rival products, analyst, shares)

21 Oct 2014

BRIEF-Actelion shares open up 4 pct

* Actelion shares open up 4 percent after raising its full-year guidance. Further company coverage: (Reporting by Joshua Franklin)

21 Oct 2014

Actelion CEO says has received no takeover approaches

ZURICH - Actelion has received no takeover bids from interested parties, the company's chief executive said on Tuesday.

21 Oct 2014

BRIEF-Actelion shares seen opening up 2.6 pct-premarket indicators

* Actelion shares seen opening up 2.6 percent, according to premarket indicators, after it raised its full-year guidance. Further company coverage: (Reporting by Joshua Franklin)

21 Oct 2014

REPEAT-UPDATE 2-AstraZeneca, Shire dive as U.S. tax move punctures deal hopes

* Seen as possible threat to Shire's agreed sale to AbbVie

23 Sep 2014

European shares bounce back, helped by earnings reports

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

European shares bounce back as Ukraine tension ease

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

European shares up as Ukraine rebels allow improved access

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks